Description

Iguratimod (T-614) is a novel small-molecule disease-modifying anti-rheumatic drug (DMARD) with potent anti-inflammatory and immunomodulatory effects. It inhibits NF-?B activation, reduces pro-inflammatory cytokines including TNF??, IL?6, IL?8, IL?1?, and COX?2, and modulates immune cell activity, offering both anti-inflammatory and cartilage-protective properties .

The Ainingdu formulation delivers a precise 25?mg dose per tablet, ideal for preclinical studies in rheumatology, cartilage protection, and autoimmune models. Produced by Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd., it holds China NMPA approval number H20244320, drug code 86901522000311, and barcode 6940119929011.

?? Only for laboratory research use. Not for clinical, therapeutic, or veterinary application.

Iguratimod Tablets Product Specifications

Iguratimod Tablets Mechanism & Research Applications

Iguratimod acts by:

• Inhibiting NF??B activation and expression of pro-inflammatory cytokines (TNF??, IL?6, IL?8, IL?1?, COX?2)

• Regulating immune cell function in autoimmune disease models

Common research applications include:

• Rheumatoid arthritis and autoimmune disease modeling

• Cytokine profiling and inflammatory pathway studies

• Cartilage protection and bone metabolism assays

• Combination therapy studies with MTX or biologic agents

Iguratimod Tablets Side Effects (Research Observations)

Preclinical and clinical data report potential effects such as:

• Elevated liver enzymes (transaminases)

• Gastrointestinal discomfort (nausea, vomiting, abdominal pain)

• Skin reactions (rash, itchiness)

• Mild hematologic changes (rare)

Monitor liver and GI markers during in vivo studies.

Safety & Handling

• Use Restriction: Laboratory research only. Not for human or veterinary use

• PPE Protocol: Gloves, lab coat, and eye protection required

• Storage: Keep sealed in a cool, dry place below 25?°C

• Disposal: Dispose of unused tablets and packaging according to institutional chemical safety protocols

Core Keywords

Iguratimod tablets, Ainingdu Iguratimod, 25?mg T?614 tablets, research DMARD, rheumatoid arthritis compound, autoimmune research reagent, Jiangsu Zhengda Iguratimod, NMPA H20244320, wholesale Iguratimod tablets, lab-use Iguratimod

Research Use Disclaimer

This product is exclusively for laboratory research purposes and not approved for clinical, therapeutic, diagnostic, or veterinary use. Misuse may pose safety and regulatory risks. Always follow institutional biosafety and handling protocols.